Education
About Us
Working with TipRanks
Follow Us
Sonnet BioTherapeutics Holdings (SONN)
NASDAQ:SONN
RESEARCH TOOLSreports
SONN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.08 - $19.30
Previous CloseN/A
Volume154.24K
Average Volume (3M)7.52M
Market Cap
$28.69M
Enterprise Value$28.96M
Total Cash (Recent Filing)$2.06M
Total Debt (Recent Filing)$90.45K
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 18, 2025EPS Estimate
-0.49Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding3,332,728
10 Day Avg. Volume9,462,011
30 Day Avg. Volume7,518,094
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)56.26
Price to Sales (P/S)0.00
P/FCF Ratio-2.59
Enterprise Value/Market Cap1.01
Enterprise Value/Revenue13.96
Enterprise Value/Gross Profit-8.38
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$1.00Price Target Upside-87.16% Downside
Rating ConsensusHold
Number of Analyst Covering0
Sonnet BioTherapeutics Holdings News
Options Prices
Currently, No data available
---
Ownership Overview
3.43% Insiders
0.22% Mutual Funds
4.22% Other Institutional Investors
92.06% Public Companies and Individual Investors
SONN FAQ
What was Sonnet BioTherapeutics Holdings’s price range in the past 12 months?
Sonnet BioTherapeutics Holdings lowest stock price was $1.08 and its highest was $19.30 in the past 12 months.
What is Sonnet BioTherapeutics Holdings’s market cap?
Sonnet BioTherapeutics Holdings’s market cap is $28.69M.
When is Sonnet BioTherapeutics Holdings’s upcoming earnings report date?
Sonnet BioTherapeutics Holdings’s upcoming earnings report date is Aug 18, 2025 which is in 30 days.
How were Sonnet BioTherapeutics Holdings’s earnings last quarter?
Currently, no data Available
Is Sonnet BioTherapeutics Holdings overvalued?
According to Wall Street analysts Sonnet BioTherapeutics Holdings’s price is currently Overvalued.
Does Sonnet BioTherapeutics Holdings pay dividends?
Sonnet BioTherapeutics Holdings does not currently pay dividends.
What is Sonnet BioTherapeutics Holdings’s EPS estimate?
Sonnet BioTherapeutics Holdings’s EPS estimate is -0.49.
How many shares outstanding does Sonnet BioTherapeutics Holdings have?
Sonnet BioTherapeutics Holdings has 3,332,728 shares outstanding.
What happened to Sonnet BioTherapeutics Holdings’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sonnet BioTherapeutics Holdings?
Currently, no hedge funds are holding shares in SONN
Sonnet BioTherapeutics Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (-87.16% Downside)
$1.00 (-87.16% Downside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.7%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.19%
12-Months-Change
Fundamentals
Return on Equity
-714.96%
Trailing 12-Months
Asset Growth
-35.08%
Trailing 12-Months
Company Description
Sonnet BioTherapeutics Holdings
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.
Technical Analysis
Kazia Therapeutics
―
Galecto
―
NLS Pharmaceutics
―
Bluejay Diagnostics
―
SciSparc Ltd.
―